Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • Immune Environment in Glioblastoma (Feb 2023)
    • Korsmeyer Award 25th Anniversary Collection (Jan 2023)
    • Aging (Jul 2022)
    • Next-Generation Sequencing in Medicine (Jun 2022)
    • New Therapeutic Targets in Cardiovascular Diseases (Mar 2022)
    • Immunometabolism (Jan 2022)
    • Circadian Rhythm (Oct 2021)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Commentaries
    • Research letters
    • Letters to the editor
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • In-Press Preview
  • Commentaries
  • Research letters
  • Letters to the editor
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
Gene expression profiling of CD8+ T cells predicts prognosis in patients with Crohn disease and ulcerative colitis
James C. Lee, … , Miles Parkes, Kenneth G.C. Smith
James C. Lee, … , Miles Parkes, Kenneth G.C. Smith
Published September 26, 2011
Citation Information: J Clin Invest. 2011;121(10):4170-4179. https://doi.org/10.1172/JCI59255.
View: Text | PDF
Research Article

Gene expression profiling of CD8+ T cells predicts prognosis in patients with Crohn disease and ulcerative colitis

  • Text
  • PDF
Abstract

Crohn disease (CD) and ulcerative colitis (UC) are increasingly common, chronic forms of inflammatory bowel disease. The behavior of these diseases varies unpredictably among patients. Identification of reliable prognostic biomarkers would enable treatment to be personalized so that patients destined to experience aggressive disease could receive appropriately potent therapies from diagnosis, while those who will experience more indolent disease are not exposed to the risks and side effects of unnecessary immunosuppression. Using transcriptional profiling of circulating T cells isolated from patients with CD and UC, we identified analogous CD8+ T cell transcriptional signatures that divided patients into 2 otherwise indistinguishable subgroups. In both UC and CD, patients in these subgroups subsequently experienced very different disease courses. A substantially higher incidence of frequently relapsing disease was experienced by those patients in the subgroup defined by elevated expression of genes involved in antigen-dependent T cell responses, including signaling initiated by both IL-7 and TCR ligation — pathways previously associated with prognosis in unrelated autoimmune diseases. No equivalent correlation was observed with CD4+ T cell gene expression. This suggests that the course of otherwise distinct autoimmune and inflammatory conditions may be influenced by common pathways and identifies what we believe to be the first biomarker that can predict prognosis in both UC and CD from diagnosis, a major step toward personalized therapy.

Authors

James C. Lee, Paul A. Lyons, Eoin F. McKinney, John M. Sowerby, Edward J. Carr, Francesca Bredin, Hannah M. Rickman, Huzefa Ratlamwala, Alexander Hatton, Tim F. Rayner, Miles Parkes, Kenneth G.C. Smith

×

Figure 2

CD patients in subgroups IBD1 and IBD2 have significantly different disease courses.

Options: View larger image (or click on image) Download as PowerPoint
CD patients in subgroups IBD1 and IBD2 have significantly different dise...
(A) Kaplan-Meier survival curves demonstrating the proportion of CD patients who did not require a subsequent treatment escalation (immunomodulator or surgery) after enrollment, as stratified by IBD1/2 subgroup (left) and ASCA serology (middle) and clinical parameters associated with complicated disease (right). Clinical parameters included age of less than 40 years at diagnosis, initial requirement for steroids, and perianal involvement. High risk of complicated disease was defined as 2 or more of these parameters; low risk was defined as fewer than 2 of these parameters. Statistical significance was determined using a log-rank test (df). Number at risk refers to the number of uncensored patients at each time point who remained at risk of requiring a treatment escalation. (B) Disease courses of all CD patients (y axis). The color of dotted lines reflects subgroup designation. In cases in which multiple treatment escalations are indicated, this universally reflects ongoing disease activity rather than intolerance to the initial treatment. Statistical significance was determined using a Fisher’s exact test (2 df). (C) Bayes’ nomogram demonstrating the effect that stratifying the CD cohorts by the IBD1/2 signature would have had upon the predicted requirement for treatment escalation: prior probability of treatment escalation, 48.6%; positive likelihood ratio, (sensitivity/[1-specificity]) 5.29 (95% CI, 1.35–21); negative likelihood ratio, ([1-sensitivity]/specificity) 0.46 (95% CI, 0.26–0.84); post-test probabilities, IBD1, 83% (95% CI, 56%–95%), and IBD2, 30% (95% CI, 20%–44%).

Copyright © 2023 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts